Prostate cancer starts in the prostate gland–and is the second most common form of cancer in men. The cancer spreads, or metastasized, from the prostate to other areas of the body with the help of the bloodstream or lymphatic system, which results in the metastasis of the tumor, leading to the development of Advanced Prostate Cancer.
According to Global cancer statistics 2012, the incidence of prostate cancer in Japan is rapidly increasing, even though it is still much lower than in Western populations. Inoue et al. reported that in a population of 151 patients with CRPC, 84% had bone metastases at diagnosis. As per Cancer Research UK, among the diagnosed prostate cancer cases in England, Scotland, 17% and 34% of prostate cancer patients have metastases at diagnosis (stage IV). It is found to be more common in the adults aged (39%) than the younger persons (30%).
Get FREE sample copy at: https://www.delveinsight.com/sample-request/castrate-resistant-prostate-cancer-market
The Castrate-Resistant Prostate Cancer (CRPC) market report also covers emerging drugs, current treatment practices, Castrate-Resistant Prostate Cancer (CRPC) market share of the individual therapies, current and forecasted CRPC Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Castrate-Resistant Prostate Cancer treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Key Benefits of Castrate-Resistant Prostate Cancer (CRPC) Market Report
Castrate-Resistant Prostate Cancer market report provides an in-depth analysis of Castrate-Resistant Prostate Cancer (CRPC) Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major markets, i.e. EU5 (Germany, Italy, Spain, France, and the UK), Japan, and the United States.
The CRPC market report will help in developing business strategies by understanding the Castrate-Resistant Prostate Cancer Market trends & developments, key players, and future market competition that will shape and drive the CRPC market in the upcoming years.
The Castrate-Resistant Prostate Cancer (CRPC) market report covers CRPC current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
The report provides a detailed assessment of the Castrate-Resistant Prostate Cancer market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
The Castrate-Resistant Prostate Cancer (CRPC) market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Castrate-Resistant Prostate Cancer (CRPC) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the Castrate-Resistant Prostate Cancer (CRPC) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Castrate-Resistant Prostate Cancer Epidemiology
The Castrate-Resistant Prostate Cancer epidemiology section covers insights about the historical and current CRPC patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Castrate-Resistant Prostate Cancer (CRPC) Drugs Uptake and Key Market Players
The Castrate-Resistant Prostate Cancer Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the CRPC market or expected to get launched in the market during the study period. The analysis covers Castrate-Resistant Prostate Cancer (CRPC) market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Table of Content
1. Key Insights
2. Executive Summary
3. Castrate-Resistant Prostate Cancer (CRPC) Competitive Intelligence Analysis
4. Castrate-Resistant Prostate Cancer (CRPC) Market Overview at a Glance
5. Castrate-Resistant Prostate Cancer (CRPC) Disease Background and Overview
6. Castrate-Resistant Prostate Cancer (CRPC) Patient Journey
7. Castrate-Resistant Prostate Cancer (CRPC) Epidemiology and Patient Population
8. Castrate-Resistant Prostate Cancer (CRPC) Treatment Algorithm, Current Treatment, and Medical Practices
9. Castrate-Resistant Prostate Cancer (CRPC) Unmet Needs
10. Key Endpoints of Castrate-Resistant Prostate Cancer (CRPC) Treatment
11. Castrate-Resistant Prostate Cancer (CRPC) Marketed Products
12. Castrate-Resistant Prostate Cancer (CRPC) Emerging Therapies
13. Castrate-Resistant Prostate Cancer (CRPC) Seven Major Market Analysis
14. Attribute Analysis
15. Castrate-Resistant Prostate Cancer (CRPC) Market Outlook (7 major markets)
16. Castrate-Resistant Prostate Cancer (CRPC) Access and Reimbursement Overview
17. KOL Views on the Castrate-Resistant Prostate Cancer (CRPC) Market.
18. Castrate-Resistant Prostate Cancer (CRPC) Market Drivers
19. Castrate-Resistant Prostate Cancer (CRPC) Market Barriers
21. DelveInsight Capabilities
*The table of contents is not exhaustive; the final content may vary.
Latest Reports By DelveInsight
Castrate Resistant Prostate Cancer Pipeline Insights
Castrate Resistant Prostate Cancer Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Castrate-Resistant Prostate Cancer (CRPC) market.
Healthcare Blogs –
Painful Diabetic Neuropathy Market Landscape
As per DelveInsight’s, the total diagnosed prevalent cases of Chronic Pain associated with Painful Diabetic Neuropathy in the 7MM is expected to increase at a CAGR of 0.64% during the study period 2018-30. The Chronic Pain associated with the Painful Diabetic Neuropathy market is estimated to increase due to advancements in healthcare technology, high healthcare expenditure, and available reimbursement policies in developed countries. The key companies operating in the Chronic Pain associated with PDN therapeutics market include Grünenthal, Daiichi Sankyo, Janssen Pharma, Pfizer, Eli Lilly, Shionogi, Ono Pharma, Fremslife, Helixmith, Aptinyx, Regenacy Pharmaceuticals, Novaremed AG, Nevro, Erchonia Corporation, Regenesis Biomedical, Abbott, Zygood, and many others. For more details, visit: Chronic Pain Associated with Painful Diabetic Neuropathy Market
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States